Braveheart Bio, Inc. — Form SCHEDULE 13D
Filed August 18, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 28/100
What the filing says
OrbiMed Advisors LLC, OrbiMed Capital GP IX LLC, and OrbiMed Genesis GP LLC filed a joint Schedule 13D on August 7, 2026 regarding their common stock position in Braveheart Bio, Inc. The filing indicates a coordinated disclosure of ownership by three OrbiMed entities under Carl L. Gordon's signature authority. No specific stake percentage, share count, or acquisition details are provided in this procedural joint filing agreement excerpt.
Why this rating
Joint filing is procedural; substance not disclosed here. Scale of ownership and business impact unknown without full 13D schedules.
See more from August 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.